Abstract
The recent recommendations of the European Treatment and Outcome Study (EUTOS) for chronic myeloid leukemia (CML) aim to standardise the reporting of molecular response (MR) as quantified by RT-quantitative polymerase chain reaction (qPCR).1 This is becoming an important issue as treatment is producing very low levels of disease in an increasing number of patients, and decisions on whether to cease or continue treatment are becoming increasingly common.
Original language | English |
---|---|
Pages (from-to) | 1630-1631 |
Number of pages | 2 |
Journal | Leukemia |
Volume | 30 |
Issue number | 7 |
DOIs | |
Publication status | Published - Jul 2016 |
Keywords
- Chronic myeloid leukaemia